CXCL11 and cholangiocarcinoma: The TRIP-Brs significantly overexpressed in BRCA, kidney-carcinoma (KIRC), cholangiocarcinoma (CHOL), lung-adenocarcinoma (LUAD; except TRIP-Br-1), colon-adenocarcinoma (COAD), esophageal-carcinoma (ESCA), uterine-endometrial-carcinoma (UCEC), and lung squamous cell carcinoma (LUSC; except TRIP-Br-1), whereas significant downregulation of TRIP-Brs was observed in KICH (kidney chromophobe) and PRAD (prostate adenocarcinoma) as compared with normal tumor tissue samples (Figures 1B–1F).